Published in Bull Cancer on July 01, 2012
Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res (2013) 2.06
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.99
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol (2009) 1.83
Brain metastases from breast carcinoma: validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score. Int J Radiat Oncol Biol Phys (2007) 1.83
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol (2011) 1.78
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol (2010) 1.68
VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer (2009) 1.45
Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI. Onkologie (2012) 1.39
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One (2012) 1.27
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour. Invest New Drugs (2009) 1.20
Sequential therapy in renal cell carcinoma. Cancer (2009) 1.18
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology (2011) 1.15
Tumor assessment criteria in phase I trials: beyond RECIST. J Clin Oncol (2012) 1.15
Inclusion of patients with advanced cancer in phase I trials: is this a tool for improving optimism and emotional well-being? J Clin Oncol (2013) 1.08
Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer (2011) 1.00
Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol (2008) 0.97
Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib. Invest New Drugs (2010) 0.95
The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer (2010) 0.94
Targeted therapy-induced radiation recall. Eur J Cancer (2013) 0.94
Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials. Clin Cancer Res (2011) 0.91
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist (2011) 0.90
Brain metastases from breast cancer: proposition of new prognostic score including molecular subtypes and treatment. J Neurooncol (2011) 0.89
Minimal residual disease in solid neoplasia: New frontier or red-herring? Cancer Treat Rev (2011) 0.88
From theoretical synergy to clinical supra-additive toxicity. J Clin Oncol (2009) 0.88
Antiangiogenic agents and late anastomotic complications. J Surg Oncol (2010) 0.88
Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. Eur J Cancer (2011) 0.86
Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen. Eur J Cancer (2012) 0.85
Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: a prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs. Eur J Cancer (2012) 0.85
Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol (2011) 0.84
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. Expert Rev Anticancer Ther (2015) 0.83
Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer. J Clin Oncol (2005) 0.83
Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer (2011) 0.83
Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials. Invest New Drugs (2011) 0.83
Changing therapeutic paradigms in castrate-resistant prostate cancer. Clin Genitourin Cancer (2010) 0.81
QT interval prolongation among patients treated with angiogenesis inhibitors. Target Oncol (2009) 0.81
Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma. Invest New Drugs (2009) 0.80
Implementing precision medicine initiatives in the clinic: a new paradigm in drug development. Curr Opin Oncol (2014) 0.79
Vascular disrupting agents: a delicate balance between efficacy and side effects. Curr Opin Oncol (2012) 0.79
Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials. Invest New Drugs (2010) 0.78
Electrolyte disorders related to EGFR-targeting drugs. Crit Rev Oncol Hematol (2009) 0.78
A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma. Urol Oncol (2011) 0.78
Targeted therapies in metastatic renal cell carcinoma: overview of the past year. Curr Urol Rep (2012) 0.78
Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma. Clin Genitourin Cancer (2012) 0.77
Trastuzumab-induced cardiotoxicity: is it time for troponin for all patients? Am J Clin Oncol (2012) 0.77
[Locally advanced prostate cancer: definition, prognosis and treatment]. Bull Cancer (2007) 0.77
Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples. Invest New Drugs (2013) 0.77
Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments. Invest New Drugs (2010) 0.77
Delivery by shock waves of active principle embedded in gelatin-based capsules. Ultrason Sonochem (2007) 0.77
New agents in metastatic prostate cancer. Eur J Cancer (2009) 0.76
Clinical benefit for patients with non-small cell lung cancer enrolled in phase I trials. Onkologie (2013) 0.76
[American Society of Clinical Oncology (ASCO) 2012 essential data: the editorial board of the Bulletin du Cancer point of view]. Bull Cancer (2012) 0.76
[American Society of Clinical Oncology (ASCO) 2011 essential data: the editorial board of the Bulletin du Cancer point of view]. Bull Cancer (2011) 0.76
Toward a better dialogue between neuro-oncologists and phase I investigators. J Clin Oncol (2012) 0.75
[Bladder cancer. Editorial]. Bull Cancer (2010) 0.75
[Cell cycle, mitosis and therapeutic applications]. Bull Cancer (2011) 0.75
[Prognostic factors for patients with brain metastases]. Bull Cancer (2013) 0.75
Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies. Oncology (2015) 0.75
False positive 2-(18)Fluroro-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with disseminated seminoma and post-chemotherapy residual masses. Clin Genitourin Cancer (2012) 0.75
[Editorial]. Bull Cancer (2014) 0.75
Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system. Anticancer Drugs (2017) 0.75
Late recurrent testicular seminoma: histological evidence is required. Oncol Res Treat (2015) 0.75
[Cannabis and cancer]. Bull Cancer (2006) 0.75
Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial. Invest New Drugs (2009) 0.75
[Bone targeted therapies: new agents]. Bull Cancer (2013) 0.75
[Brain metastases from breast cancer: usefulness and limits of prognostic scores]. Bull Cancer (2011) 0.75
Rhinitis in patients treated with a combination of an mTOR inhibitor and an EGFR inhibitor. Onkologie (2010) 0.75
[A point on a new year]. Bull Cancer (2016) 0.75
Wound healing delay after central venous access following DCF/VEGF-trap therapy. Invest New Drugs (2009) 0.75
[Nutrition and cancer: questions of balance]. Bull Cancer (2009) 0.75
Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report. Invest New Drugs (2009) 0.75
[RB, guardian of prostatic tumor progression]. Bull Cancer (2011) 0.75
[Metronomic chemotherapy in 2011: update and perspectives]. Bull Cancer (2011) 0.75